ALTEOGEN Inc. (KOSDAQ:196170)

South Korea flag South Korea · Delayed Price · Currency is KRW
446,000
-7,000 (-1.55%)
Oct 24, 2025, 3:30 PM KST
-1.55%
Market Cap23.85T
Revenue (ttm)158.06B
Net Income (ttm)94.29B
Shares Out53.48M
EPS (ttm)1,617.35
PE Ratio275.76
Forward PE91.14
Dividendn/a
Ex-Dividend Daten/a
Volume293,517
Average Volume382,919
Open456,000
Previous Close453,000
Day's Range443,500 - 456,000
52-Week Range274,000 - 529,000
Beta1.08
RSI46.40
Earnings DateNov 13, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 155
Stock Exchange KOSDAQ
Ticker Symbol 196170
Full Company Profile

Financial Performance

Financial Statements

News

FDA Clears Merck's One-Minute Cancer Shot

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...

4 weeks ago - Benzinga